Artificial intelligence in Chinese healthcare: a review of applications and future prospects
Biomedical Engineering Letters · 2025-11 · 15 (6) · 1065-1072
DOI: 10.1007/s13534-025-00515-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomedical Engineering Letters, online erschienen am 23.10.2025. Verfasst von Zihuan Wang. Beteiligte Einrichtung: National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.
Abstract (Originalsprache)
China’s healthcare infrastructure faces growing population pressure and resource gaps. This review explores how AI applications, regulatory frameworks, and commercialization pathways are reshaping China’s healthcare delivery system and global innovation standards. China’s AI healthcare market is expected to grow from $900 million in 2020 to $1.59 billion in 2023, and is expected to reach $18.88 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 42.5%. The National Medical Products Administration (NMPA) expects to approve 59 Class III AI devices by 2023, compared with just nine in 2020. Key applications include the widespread use of AI technology in lesion identification; a telemedicine platform serving 13 million users; and AI drug development that shortens the development cycle from 4 to 18 months. Regulatory pillars include the Personal Information Protection Law, which requires explicit consent before processing health data, and NMPA guidelines, which require all AI medical software to undergo three types of review. China’s unique combination of centralized health data, policy incentives, and rapid commercialization has created a globally competitive AI medical ecosystem. Continued development requires addressing issues such as algorithm transparency, cross-border data governance, and international regulatory coordination.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Engineering Research Center of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
- Center of Optometry International Innovation of Wenzhou, China Eye Valley, Wenzhou, China.
- Institute of Engineering Research, Seoul National University, Seoul, South Korea.
ORCID-Profile: Zihuan Wang
Förderung
- Seoul National University
Zitieren
APA
Wang, Z. (2025). Artificial intelligence in Chinese healthcare: a review of applications and future prospects. Biomedical Engineering Letters, 15(6), 1065-1072. https://doi.org/10.1007/s13534-025-00515-2
Vancouver
Wang Z. Artificial intelligence in Chinese healthcare: a review of applications and future prospects. Biomedical Engineering Letters. 2025;15(6):1065-1072. doi:10.1007/s13534-025-00515-2
BibTeX
@article{Wang2025,
author = {Wang, Zihuan},
title = {Artificial intelligence in Chinese healthcare: a review of applications and future prospects},
journal = {Biomedical Engineering Letters},
year = {2025},
volume = {15},
number = {6},
pages = {1065--1072},
doi = {10.1007/s13534-025-00515-2}
}
EUVIMED